{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T10:03:27Z","timestamp":1769940207381,"version":"3.49.0"},"reference-count":31,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2001,12,20]],"date-time":"2001-12-20T00:00:00Z","timestamp":1008806400000},"content-version":"vor","delay-in-days":84,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2001,9,27]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p>Rabeprazole is a new, potent, proton pump inhibitor. The metabolism of rabeprazole is less dependent on CYP2C19 genetic polymorphism.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>A total of 102 <jats:italic>Helicobacter pylori<\/jats:italic>\u2010positive patients with gastric ulcer were randomly allocated to three groups: rabeprazole 10\u2003mg (RAC10), rabeprazole 20\u2003mg (RAC20) or rabeprazole 40\u2003mg (RAC40) plus amoxicillin 750\u2003mg and clarithromycin 200\u2003mg twice daily for 7\u2003days. CYP2C19 genotype was determined by the polymerase chain reaction\u2010restriction fragment length polymorphism method.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>All\u2010patients\u2010treated\u2010based eradication rates in patients treated with RAC10, RAC20 and RAC40 were 83%, 77% and 90%, respectively, and per protocol\u2010based eradication rates were 83%, 80% and 90%, respectively. The eradication rates in the three groups were not significantly different. There was also no significant difference between the all\u2010patients\u2010treated\u2010based eradication rate in CYP2C19 extensive metabolizers and that in poor metabolizers (86% vs. 77%). Adverse events were 12% in extensive metabolizers and 23% in poor metabolizers, and the difference in these incidence rates was also not statistically significant.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions:<\/jats:title><jats:p>Triple therapy with 10\u2003mg of rabeprazole combined with amoxicillin\/clarithromycin is effective for Japanese patients with <jats:italic>H. pylori<\/jats:italic> infection, and the <jats:italic>H. pylori<\/jats:italic> eradication rate is not affected by CYP2C19 genetic polymorphism.<\/jats:p><\/jats:sec>","DOI":"10.1046\/j.1365-2036.2001.01063.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T03:45:08Z","timestamp":1047354308000},"page":"1479-1484","source":"Crossref","is-referenced-by-count":51,"title":["Efficacy of triple therapy with rabeprazole for <i>Helicobacter pylori<\/i> infection and CYP2C19 genetic polymorphism"],"prefix":"10.1111","volume":"15","author":[{"given":"K.","family":"Hokari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Miyagishima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Kudo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Nishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Ishizuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Komatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Mizushima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Kagaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Hige","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Asaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2001,12,20]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/path.1711540203"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.1991.tb01448.x"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(93)90938-D"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(88)90929-4"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(93)91409-F"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-199409000-00004"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-5378.1996.tb00027.x"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(99)70119-8"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199631010-00002"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-199610001-00005"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1999.00440.x"},{"key":"e_1_2_5_13_2","unstructured":"National Committee for Clinical Laboratory Standards.Performance Standards for Antimicrobial Susceptibility Testing; Ninth Informational Supplement M100\u2010S9. NCCLS guideline Pennsylvania 1999."},{"key":"e_1_2_5_14_2","first-page":"36","article-title":"Clinical studies of 13C\u2010urea breath test in Japan","volume":"33","author":"Kato M","year":"1998","journal-title":"J Gastroenterol"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/PL00009968"},{"key":"e_1_2_5_16_2","doi-asserted-by":"crossref","first-page":"15\u2003419","DOI":"10.1016\/S0021-9258(17)40694-6","article-title":"The major genetic defect responsible for the polymorphism of S\u2010mephenytoin metabolism in humans","volume":"269","author":"De Morasis SMF","year":"1994","journal-title":"J Biol Chem"},{"key":"e_1_2_5_17_2","first-page":"594","article-title":"Identification of a new genetic defect responsible for the polymorphism of S\u2010mephenytoin metabolism in Japanese","volume":"46","author":"De Morasis SMF","year":"1994","journal-title":"Mol Pharmacol"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-199412000-00001"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(97)80027-3"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1998.00418.x"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1005409310412"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.41.4.452"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2000.00772.x"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2000.00774.x"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199529030-00005"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(96)90214-3"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-129-12-199812150-00006"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(99)70017-2"},{"key":"e_1_2_5_29_2","doi-asserted-by":"crossref","unstructured":"AsakaM SugiyamaT KatoM et\u2003al.A multicenter double\u2010blind study on the triple therapy with lansoprazole\/amoxicillin\/clarithromycin for eradication ofHelicobacter pyloriin Japanese peptic ulcer patients.Helicobacter2001;6: in press.","DOI":"10.1046\/j.1523-5378.2001.00037.x"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-5378.1999.99299.x"},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2000.00807.x"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.2.458-461.2000"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2036.2001.01063.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2036.2001.01063.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2036.2001.01063.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T15:24:24Z","timestamp":1695828264000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2036.2001.01063.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,9,27]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2001,9,27]]}},"alternative-id":["10.1046\/j.1365-2036.2001.01063.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2036.2001.01063.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,9,27]]}}}